
    
      1. To evaluate the safety and tolerability of oral Selatinib Ditosilate Tablets, and
           explore the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).

        2. To determine the pharmacokinetic profile of single and multi oral Selatinib Ditosilate
           Tablets .

        3. To determine preliminary dose and regimen for phase II study of oral Selatinib
           Ditosilate Tablets.

        4. To assess preliminary antitumor activity .
    
  